Key Highlights
- About 34 percent: Monday's fall for Sunshine Biopharma (NASDAQ:SBFM) to near USD 0.44, a Market Value near USD 2.5 million, per published market data, with no same-day company announcement identified in the materials reviewed for this article.
- 1-for-10: the reverse split effective June 1, 2026 to regain Nasdaq's minimum bid compliance, reducing shares from 21.24 million to about 2.12 million, a price reset the stock has since reversed, simple arithmetic on the company's figures.
- USD 6 million: the gross proceeds of the May 2026 public offering of 12 million units at USD 0.50, each with two Series C warrants at USD 0.50, placed through Aegis Capital for Sunshine Biopharma (NASDAQ:SBFM).
- 60 generic drugs: the Canadian prescription portfolio Sunshine markets, with 12 more launches planned through the rest of 2026, alongside its K1.1 mRNA liver cancer program and a protease inhibitor program for coronaviruses, according to the company.
The Latest Move
Sunshine Biopharma fell about 34 percent on Monday, October 5, 2026 to near USD 0.44, after trading down 20.5 percent to USD 0.53 premarket. Its market value was about USD 2.5 million, per published market data. No same-day announcement was identified. At USD 0.44 the stock is about 85 percent below ten times the USD 0.30 pre-split price in late May, simple arithmetic, despite the 1-for-10 reverse split. The company is based in Fort Lauderdale, Florida, according to its offering announcements.
The Split and the Offering
The company approved a 1-for-10 reverse split effective June 1, 2026 to regain Nasdaq compliance, cutting shares from about 21.24 million to 2.12 million. In May it sold 12 million units at USD 0.50 for USD 6 million, each unit with two Series C warrants at USD 0.50, with Aegis Capital as Placement agent. Warrants and later issuance can raise the share count well above the post-split figure. Shareholders had earlier authorized a possible split of up to 1-for-10 at a meeting held on March 6, 2026.
Business and Risks
Sunshine, based in Florida with Canadian operations, markets 60 generic prescription drugs in Canada and expects 12 more launches in 2026. It is developing K1.1 mRNA for liver cancer and a PLpro protease inhibitor program. The company reported modest Revenue growth and cost tightening for 2025, and its chief operating officer resigned suddenly. Risks include dilution, a tiny market value and continued Nasdaq listing requirements. At a market value of about USD 2.5 million, a single USD 6 million raise exceeds the company's entire stock market value.
Where Things Stand
The drop fits a pattern of dilution and price pressure, not a single event. Sunshine Biopharma (NASDAQ:SBFM) did a 1-for-10 reverse split in June, yet by October 5, 2026 it was trading near USD 0.44 with a market value of USD 2.5 million, about 85 percent below ten times its pre-split price. A USD 6 million offering with two warrants per unit adds potential supply. Its generics Business is real, but small. Next catalysts are a further Nasdaq notice, additional financing and quarterly results, none of which has a confirmed date.






Please wait processing your request...